<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-17_23-54-14</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
High-grade serous tubo-ovarian carcinoma with peritoneal spread post-interval debulking and early adjuvant platinum–taxane, responding biochemically but with staging, residual disease, and thrombosis status still insufficiently defined for maintenance decisions.

Core Treatment Strategy:
- Maintain current systemic-therapy trajectory today; do not change regimen until full chemo record, ECOG, and labs are reviewed (all unknown).  
- Urgently obtain operative note and full pathology/IHC/molecular reports to define FIGO stage, primary site, and R0/R1/R2 status (unknown).  
- Arrange contrast-enhanced abdominopelvic CT or PET/CT with RECIST to assess residual disease and re-evaluate left ovarian vein thrombosis (current imaging date unknown).  
- Clarify anticoagulation use and VTE/bleeding risks; formalize a thrombosis management and imaging follow‑up plan once data are available (unknown).  

Change Triggers:
- If updated imaging or clinical data show progression or intolerance, reassess systemic therapy intent and consider modifying or pausing active treatment.  
- If chemotherapy course, response, and residual burden confirm standard 1L completion and good status, formally discuss and choose maintenance versus surveillance strategy.</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>卵巢癌新辅1程后：代诊：卵巢癌术前CA125&gt;1000 CA724 81 余肿标正常2023.4.21 外院腹盆腔CT：附件占位 大网膜 肠系膜结节 多发转移；乙状结肠增厚，建议肠镜完善检查；腹膜后淋巴结增多自述肠镜无异常胃镜未做2023.4.25 腹腔镜活检：高浆2023.4.29 紫杉醇+卡铂化疗1程初诊影像复片（2023.4CT）：右侧附件占位MT可能，伴大网膜、肠系膜腹膜混浊增厚伴结节，M可能；乙状结肠少增厚，建议肠镜2023.06.21我院手术，术后病理：标本类型:次广泛子宫+双附件+盆底腹膜+盆腹腔多处病灶肿瘤大小:左侧：2.8*1.5*1.3cm；右侧：3*1.6*1.3cm肿瘤侧别:双侧卵巢病理类型:少量低分化癌，伴大量砂粒体、多量多核巨细胞反应，符合高级别浆液性癌伴治疗后改变。其他部位情况:左输卵管:见大量砂粒体右输卵管:见癌累及子宫内膜:萎缩改变宫颈:慢性炎子宫肌层:肌壁间平滑肌瘤（1枚，直径0.5cm）；腺肌症；局灶浆膜面及肌壁见癌累及。盆腹腔多部位病灶:（横结肠壁结节、大网膜、右侧膈肌肿瘤）均见癌累及；（乙结肠系膜结节、盆底腹膜)少量癌累及；（阑尾）慢性炎，浆膜面见癌累及。其他:/备注:/7.5外院TC方案化疗1次7.20 外院CA125：81.5 HE4：73.59基因检测：BRCA1,2，HRD（-），TP53，PIK3A（+）复片：卵巢癌术后一月，腹盆腔腹膜浑浊伴渗出改变，请复查。左侧卵巢静脉内栓子形成，请结合临床。</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;Unknown&quot;,&quot;CA125&quot;:&quot;81.5&quot;,&quot;HE4&quot;:&quot;73.59&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Wildtype&quot;,&quot;BRCA2&quot;:&quot;Wildtype&quot;,&quot;CURRENT_STATUS&quot;:&quot;Unknown&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;少量低分化癌&quot;,&quot;大量砂粒体&quot;,&quot;多核巨细胞反应&quot;],&quot;histology&quot;:&quot;少量低分化癌，伴大量砂粒体、多量多核巨细胞反应，符合高级别浆液性癌伴治疗后改变。&quot;,&quot;laterality&quot;:&quot;Bilateral&quot;,&quot;primary&quot;:&quot;Ovarian cancer&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;HRD&quot;:&quot;Negative&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Unknown&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;1&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;intent&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;紫杉醇+卡铂&quot;,&quot;start_date&quot;:&quot;2023-04-29&quot;},{&quot;cycles&quot;:&quot;1&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;intent&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;TC&quot;,&quot;start_date&quot;:&quot;2023-07-05&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;&quot;,&quot;evidence_type&quot;:&quot;Unknown&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;2023-04-29&quot;,&quot;status&quot;:&quot;Unknown&quot;},{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;&quot;,&quot;evidence_type&quot;:&quot;Unknown&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;2023-07-05&quot;,&quot;status&quot;:&quot;Unknown&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Unknown&quot;,&quot;RELAPSE&quot;:&quot;Unknown&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;&quot;,&quot;type&quot;:&quot;Unknown&quot;},&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2023-06-21&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;次广泛子宫+双附件+盆底腹膜+盆腹腔多处病灶&quot;},&quot;VISIT_DATE&quot;:&quot;2023-07-25&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;last_platinum_end_date&quot;:&quot;Unknown&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;Unknown&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;&gt;1000&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2023-07-20&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;81.5&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;Unknown&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2023-07-20&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;73.59&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;Unknown&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2023-04-29&quot;,&quot;description&quot;:&quot;First cycle paclitaxel + carboplatin&quot;,&quot;type&quot;:&quot;ChemoStart&quot;},{&quot;date&quot;:&quot;2023-06-21&quot;,&quot;description&quot;:&quot;Surgical resection&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2023-07-05&quot;,&quot;description&quot;:&quot;External TC regimen chemotherapy&quot;,&quot;type&quot;:&quot;ChemoStart&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Unknown&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[&quot;HRD: Negative&quot;,&quot;BRCA1: Wildtype&quot;,&quot;BRCA2: Wildtype&quot;],&quot;somatic&quot;:[&quot;HRD: Negative&quot;,&quot;BRCA1: Wildtype&quot;,&quot;BRCA2: Wildtype&quot;]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;紫杉醇+卡铂&quot;,&quot;TC&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[],&quot;date&quot;:&quot;2023-04-25&quot;,&quot;diagnosis&quot;:&quot;高浆&quot;,&quot;grade&quot;:&quot;Unknown&quot;,&quot;ihc&quot;:[],&quot;involvement_sites&quot;:[],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;腹腔镜活检：高浆&quot;,&quot;sample_type&quot;:&quot;Biopsy&quot;,&quot;site&quot;:&quot;Unknown&quot;,&quot;tumor_size&quot;:&quot;Unknown&quot;,&quot;uncertainty_or_missing&quot;:[]},{&quot;components&quot;:[&quot;Left ovary tumor 2.8*1.5*1.3cm&quot;,&quot;Right ovary tumor 3*1.6*1.3cm&quot;,&quot;Left fallopian tube: 大量砂粒体&quot;,&quot;Right fallopian tube: 癌累及&quot;,&quot;Endometrium: 萎缩改变&quot;,&quot;Cervix: 慢性炎&quot;,&quot;Myometrium: 平滑肌瘤 0.5cm; 腺肌症; 局灶浆膜面及肌壁见癌累及&quot;,&quot;Multiple peritoneal lesions (transverse colon wall nodule, omentum, right diaphragm tumor) all cancer involvement&quot;,&quot;Sigmoid mesentery nodule and pelvic floor peritoneum: small cancer involvement&quot;,&quot;Appendix: chronic inflammation, serosa cancer involvement&quot;],&quot;date&quot;:&quot;2023-06-21&quot;,&quot;diagnosis&quot;:&quot;少量低分化癌，伴大量砂粒体、多量多核巨细胞反应，符合高级别浆液性癌伴治疗后改变。&quot;,&quot;grade&quot;:&quot;Unknown&quot;,&quot;ihc&quot;:[],&quot;involvement_sites&quot;:[&quot;Left fallopian tube&quot;,&quot;Right fallopian tube&quot;,&quot;Endometrium&quot;,&quot;Cervix&quot;,&quot;Myometrium&quot;,&quot;Transverse colon wall&quot;,&quot;Omentum&quot;,&quot;Right diaphragm&quot;,&quot;Sigmoid mesentery&quot;,&quot;Pelvic floor peritoneum&quot;,&quot;Appendix serosa&quot;],&quot;laterality&quot;:&quot;Bilateral&quot;,&quot;molecular&quot;:[{&quot;result&quot;:&quot;BRCA1,2; HRD(-); TP53; PIK3A(+)&quot;,&quot;test&quot;:&quot;Genetic testing&quot;}],&quot;raw_text&quot;:&quot;标本类型:次广泛子宫+双附件+盆底腹膜+盆腹腔多处病灶 肿瘤大小:左侧：2.8*1.5*1.3cm；右侧：3*1.6*1.3cm 肿瘤侧别:双侧卵巢 病理类型:少量低分化癌，伴大量砂粒体、多量多核巨细胞反应，符合高级别浆液性癌伴治疗后改变。 其他部位情况:左输卵管:见大量砂粒体 右输卵管:见癌累及 子宫内膜:萎缩改变 宫颈:慢性炎 子宫肌层:肌壁间平滑肌瘤（1枚，直径0.5cm）；腺肌症；局灶浆膜面及肌壁见癌累及。 盆腹腔多部位病灶:（横结肠壁结节、大网膜、右侧膈肌肿瘤）均见癌累及；（乙结肠系膜结节、盆底腹膜)少量癌累及；（阑尾）慢性炎，浆膜面见癌累及。&quot;,&quot;sample_type&quot;:&quot;Surgical resection specimens&quot;,&quot;site&quot;:&quot;Uterus, bilateral adnexa, pelvic peritoneum, multiple intraabdominal lesions&quot;,&quot;tumor_size&quot;:&quot;Left 2.8x1.5x1.3 cm; Right 3x1.6x1.3 cm&quot;,&quot;uncertainty_or_missing&quot;:[]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Adnexa&quot;,&quot;Omentum&quot;,&quot;Mesentery&quot;,&quot;Sigmoid colon&quot;,&quot;Retroperitoneal lymph nodes&quot;],&quot;date&quot;:&quot;2023-04-21&quot;,&quot;findings&quot;:[&quot;Adnexal mass&quot;,&quot;Omental and mesenteric nodules&quot;,&quot;Multiple metastases&quot;,&quot;Sigmoid colon thickening&quot;,&quot;Increased retroperitoneal lymph nodes&quot;],&quot;impression&quot;:&quot;Adnexal mass with omental and mesenteric nodules, multiple metastases; sigmoid colon thickening; recommend colonoscopy&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;Abdominopelvic peritoneum&quot;,&quot;Left ovarian vein&quot;],&quot;date&quot;:&quot;Unknown&quot;,&quot;findings&quot;:[&quot;Peritoneal haziness with effusion&quot;,&quot;Left ovarian vein thrombus&quot;],&quot;impression&quot;:&quot;Postoperative abdominopelvic peritoneal haziness with effusion; left ovarian vein thrombosis&quot;,&quot;modality&quot;:&quot;Other&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2023-04-21&quot;,&quot;description&quot;:&quot;External abdominopelvic CT showing adnexal mass, omentum and mesenteric nodules, multiple metastases; sigmoid colon thickening; increased retroperitoneal lymph nodes.&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Adnexal mass, omental and mesenteric nodules, multiple metastases&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2023-04-25&quot;,&quot;description&quot;:&quot;Laparoscopic biopsy: 高浆&quot;,&quot;event_type&quot;:&quot;Pathology&quot;,&quot;key_result&quot;:&quot;高浆&quot;,&quot;regimen_or_test&quot;:&quot;Laparoscopic biopsy&quot;},{&quot;date&quot;:&quot;2023-04-29&quot;,&quot;description&quot;:&quot;First cycle paclitaxel + carboplatin&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;1 cycle administered&quot;,&quot;regimen_or_test&quot;:&quot;紫杉醇+卡铂&quot;},{&quot;date&quot;:&quot;2023-06-21&quot;,&quot;description&quot;:&quot;Surgery with specimens: subextensive hysterectomy + bilateral adnexa + pelvic floor peritoneum + multiple intraabdominal lesions; postoperative pathology consistent with treated high-grade serous carcinoma.&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Postop pathology: 高级别浆液性癌伴治疗后改变&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2023-07-05&quot;,&quot;description&quot;:&quot;External hospital TC regimen chemotherapy given once&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;1 cycle administered&quot;,&quot;regimen_or_test&quot;:&quot;TC&quot;},{&quot;date&quot;:&quot;2023-07-20&quot;,&quot;description&quot;:&quot;Tumor markers: CA125 81.5; HE4 73.59&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 81.5; HE4 73.59&quot;,&quot;regimen_or_test&quot;:&quot;CA125, HE4&quot;},{&quot;date&quot;:&quot;Unknown&quot;,&quot;description&quot;:&quot;Genetic testing reported: BRCA1,2; HRD(-); TP53; PIK3A(+)&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;BRCA1/2; HRD negative; PIK3A positive&quot;,&quot;regimen_or_test&quot;:&quot;Genetic testing&quot;},{&quot;date&quot;:&quot;Unknown&quot;,&quot;description&quot;:&quot;Postoperative re-evaluation: abdominopelvic peritoneal haziness with effusion; left ovarian vein thrombosis noted.&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Peritoneal haziness with effusion; left ovarian vein thrombosis&quot;,&quot;regimen_or_test&quot;:&quot;Follow-up imaging&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before confirming chemo/maintenance, we need exact R0/R1/R2 status, full chemo details, ECOG, and updated imaging including thrombus reassessment.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Please arrange and report contrast-enhanced abdominopelvic imaging with RECIST assessment and explicit comment on left ovarian vein thrombosis evolution.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Before finalizing systemic and maintenance plans, we urgently need the operative report with explicit FIGO stage and R0/R1/R2 status, plus a detailed chemo summary (cycles, doses, toxicities, completion).</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>radiologist</td><td>Please clarify on latest contrast imaging the extent of residual peritoneal disease versus postsurgical change, assess retroperitoneal nodes and sigmoid thickening, and comment on evolution of the left ovarian vein thrombosis.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>chair</td><td>Current imaging timeline and modality details are incomplete/undated (e.g., postoperative study marked &#x27;Unknown&#x27;), which limits reliable interpretation of trends and response.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>No post-chemotherapy or post-debulking contrast-enhanced CT/MRI/PET is available to quantify residual disease or thrombus status; updated imaging is essential for current disease assessment and ovarian vein thrombosis follow-up.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>Primary site (tubal vs ovarian vs peritoneal), explicit FIGO stage, and R0/R1/R2 status remain undefined; I also lack the full histology/IHC and detailed molecular report, which are critical for accurate staging documentation and biomarker confirmation.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>No PET/CT is available; updated PET/CT or contrast CT is critical now to distinguish residual disease from postoperative change and better define current stage/burden.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>radiologist</td><td>Please prioritize updated cross-sectional imaging (CT or PET/CT) with clear description of peritoneal vs postoperative changes and ovarian vein thrombosis status.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Post-NACT interval surgery for high-grade serous ovarian carcinoma; continue adjuvant platinum-taxane to complete standard first-line course if tolerable.  \n- Clarify FIGO stage, residual disease status, and completeness of cytoreduction from op note/path report before finalizing adjuvant strategy.  \n- Consider maintenance approach post-chemotherapy completion, tailored to BRCA/HRD-negative status and response depth (CA125, imaging).  \n- Urgently confirm and manage left ovarian vein thrombosis (anticoagulation plan, duration) and assess bleeding/VTE risk.  \n- Update ECOG performance status, current symptoms, full labs (CBC, renal, hepatic) and latest post-op imaging before firm treatment decisions.&quot;,
  &quot;oncologist&quot;: &quot;- High-grade serous ovarian cancer, bilateral, post-surgery on 2023-06-21 with adjuvant first-line platinum/taxane ongoing; completion status unclear.  \n- CA125 markedly decreased from &gt;1000 to 81.5 by 2023-07-20, suggesting response, but imaging correlation is unknown/needs update.  \n- HRD- and BRCA-wildtype germline and somatic; impacts maintenance options and expected benefit from targeted agents.  \n- Organ function, ECOG performance, residual disease status (R0/R1/R2), and detailed imaging after surgery are unknown/need update.  \n- Clarify chemotherapy plan: intended total cycles, tolerance/toxicities, and whether any maintenance strategy has been started or planned.&quot;,
  &quot;radiologist&quot;: &quot;- CT shows adnexal mass with omental/mesenteric nodules and retroperitoneal lymphadenopathy, compatible with peritoneal metastatic disease [@IMAGING_STUDIES|2023-04-21].  \n\n- Sigmoid colon wall thickening; direct visualization (endoscopy) needed to assess for primary or secondary involvement [@IMAGING_STUDIES|2023-04-21].  \n\n- Postoperative abdominopelvic peritoneal haziness with effusion; differentiate evolving postsurgical change from residual peritoneal disease on follow-up imaging [@IMAGING_STUDIES|Unknown].  \n\n- Left ovarian vein thrombosis present; requires correlation for anticoagulation management and interval imaging to document stability/resolution [@IMAGING_STUDIES|Unknown].  \n\n- No interval or RECIST-style trend data; updated contrast-enhanced CT or MRI needed to assess current disease burden and treatment response.&quot;,
  &quot;pathologist&quot;: &quot;- Histology consistent with high-grade serous carcinoma involving bilateral ovaries and multiple peritoneal/serosal sites, post-treatment changes noted [@HISTOLOGY_AND_IHC|2023-06-21].  \n- Exact primary site (fimbrial tube vs ovarian vs peritoneal) not explicitly assigned; clarification from original full report needed.  \n- No formal FIGO stage documented; based on described spread, stage IIIC–IV likely but needs explicit staging confirmation.  \n- BRCA1/2 wildtype and HRD-negative status documented; TP53 and PIK3CA mutations reported, but detailed molecular report/date are missing [@HISTOLOGY_AND_IHC|2023-06-21].  \n- IHC panel (WT1, p53 pattern, ER/PR, PAX8, Ki-67, MMR proteins) not provided; full IHC report needed.&quot;,
  &quot;nuclear&quot;: &quot;- No PET/CT imaging is available; metabolic disease distribution and intensity are currently unknown/needs update.  \n\n- Prior CT shows adnexal mass with omental/mesenteric nodules and sigmoid thickening, suspicious for peritoneal carcinomatosis and possible bowel involvement [@IMAGING_CONTEXT|2023-04-21].  \n\n- Postoperative abdominopelvic haziness and effusion may represent postoperative change versus residual peritoneal disease; distinction needs PET/CT correlation [@IMAGING_CONTEXT|Unknown].  \n\n- PET/CT would help differentiate postoperative inflammation from viable tumor and refine staging or recurrence suspicion, especially in peritoneum and bowel.  \n\n- For further opinion, upload most recent PET/CT report and images, plus operative/pathology details and current tumor markers.&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Do not alter current systemic therapy until full chemotherapy record, ECOG, and labs are obtained; status currently unknown/needs update.  \n- Urgently obtain and review operative note and complete pathology/IHC/molecular reports to define FIGO stage and R0/R1/R2 status; currently unknown/needs update.  \n- Arrange contrast-enhanced abdominopelvic CT or PET/CT with RECIST, explicitly assessing peritoneal disease and left ovarian vein thrombosis; current postoperative imaging date unknown/needs update.  \n- Confirm presence and timing of left ovarian vein thrombosis and current anticoagulation/VTE risk assessment; details unknown/needs update.  \n- After completing first-line platinum–taxane (cycles and tolerance unknown/needs update) and imaging response assessment, revisit maintenance versus surveillance in BRCA/HRD‑negative context.&quot;,
    &quot;oncologist&quot;: &quot;- Continue and, if feasible, complete first-line platinum–taxane; document total cycles, dates, doses, and toxicities (currently unknown).  \n- Obtain operative and full pathology reports to define primary site, FIGO stage, and R0/R1/R2 status (currently unknown).  \n- Arrange updated contrast CT or PET/CT with RECIST to distinguish residual disease from postoperative change and reassess ovarian vein thrombosis.  \n- Check ECOG, symptoms, CBC, renal/hepatic function, and coagulation profile to confirm systemic-therapy fitness and guide anticoagulation (all unknown).  \n- After chemotherapy completion and imaging response assessment, decide between active maintenance versus surveillance, considering BRCA/HRD-negative and toxicity/quality-of-life balance.&quot;,
    &quot;radiologist&quot;: &quot;- Obtain complete operative and pathology reports to define primary site, FIGO stage, and R0/R1/R2 status (currently unknown).  \n\n- Arrange updated contrast-enhanced CT or PET/CT to assess peritoneal/omental disease, retroperitoneal nodes, and distinguish postoperative change vs residual disease (none available; unknown).  \n\n- On the same imaging, specifically re-evaluate left ovarian vein thrombosis burden and any new thrombosis or embolic complications (current status unknown).  \n\n- Ensure any prior or planned endoscopic evaluation of sigmoid thickening is documented and correlated with cross-sectional imaging findings (results unknown).  \n\n- After updated imaging, formalize RECIST-style measurements to support response assessment and future surveillance comparisons (no RECIST baseline currently documented; unknown).&quot;,
    &quot;pathologist&quot;: &quot;- Confirm primary site (tube/ovary/peritoneum) and assign explicit FIGO stage after full op note and complete pathology review [@HISTOLOGY_AND_IHC|2023-06-21].  \n- Document cytoreduction status (R0/R1/R2) and residual disease map using operative findings plus updated contrast CT or PET/CT (currently missing).  \n- Obtain and integrate full IHC panel and detailed molecular report to solidify high-grade serous classification and biomarker profile [@HISTOLOGY_AND_IHC|2023-06-21].  \n- Correlate pathology with new imaging to distinguish residual tumor from postoperative change, especially peritoneal lesions and sigmoid thickening (endoscopy results unknown).  \n- After staging and residual disease are clarified, update MDT record to support systemic/maintenance decisions tailored to BRCA/HRD-negative status [@MOLECULAR|Unknown].&quot;,
    &quot;nuclear&quot;: &quot;- Obtain and review full operative and pathology reports to assign definitive FIGO stage and R0/R1/R2 status (unknown/needs update).  \n\n- Arrange updated contrast-enhanced CT or PET/CT to assess peritoneal disease, retroperitoneal nodes, and postoperative changes, with RECIST if possible (unknown/needs update).  \n\n- Specifically evaluate sigmoid colon thickening with imaging ± endoscopy to clarify primary involvement versus secondary serosal disease (unknown/needs update).  \n\n- Reassess left ovarian vein thrombosis with targeted imaging and document anticoagulation strategy and follow-up plan (unknown/needs update).  \n\n- After imaging and completion of first-line chemotherapy are clarified, reassess disease burden and performance status to guide maintenance versus surveillance (unknown/needs update).&quot;
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Selected Clinical Context (JSON)</summary>
    <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Global Guideline RAG</summary>
    <h3>RAG Query</h3>
    <pre>High‑grade serous ovarian carcinoma, platinum exposure limited (2 cycles); extensive peritoneal/omental/colon wall/diaphragmatic involvement; BRCA1/2 and HRD negative, PIK3CA positive, TP53 mutated; postoperative left ovarian vein thrombosis—guideline‑based systemic therapy and maintenance options?</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre>RAG Evidence Pack (top=5):
[1] score=0.6605 nccn_ovariancancer_v3_2025__v00000000 [PAGE 18]
    Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Gui…
[2] score=0.6553 nccn_ovariancancer_v3_2025__v00000000 [PAGE 11]
    Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Gui…
[3] score=0.6421 nccn_ovariancancer_v3_2025__v00000000 [PAGE 14]
    Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Gui…
[4] score=0.6406 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCC…
[5] score=0.6383 nccn_ovariancancer_v3_2025__v00000000 [PAGE 4]
    • Bevacizumab used as part of primary therapy BRCA1/2 wild-type or unknown, HR deficient, maintenance therapy regimen added: Olaparib (category 2B). LCOC-7 • Recurrence therapy Specific regimens removed from this page; all listed in Systemic Therapy sections (OV-C 8 and OV-C 9). OV-C (8 of 12) • U…</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6605252623558044,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 18,
    &quot;text&quot;: &quot;Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nClear Cell Carcinoma of the Ovary\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nClear cell carcinoma\nof the ovaryg,h,i\nStage\nIC2– IC3\nStage IA\nIB, IC1\nStage II–IV\nIV platinum-based therapy\n(see primary regimens for stage I disease\n[OV-C, 5 of 12])\nIV platinum-based therapy\n(see primary regimens for stage I disease\n[OV-C, 5 of 12])\nor\nObserveg\nSystemic therapy\n(OV-C, 6 of 12)\nLCOC-3\nPATHOLOGIC\nDIAGNOSISa\nADJUVANT TREATMENTf\nMONITORING/\nFOLLOW-UP\nMonitoring/Follow-up\n(including tumor testing)\nand\nRecurrence therapyj\n(OV-6)\nIf known BRCA1/2\nmutation, consider\nmaintenance therapy\n(post-primary therapy)\n(OV-5)\na WHO Histologic Classification (OV-E).\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ng If not previously done, consider surgical staging and resection of residual disease (OV-3).&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6553361415863037,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 11,
    &quot;text&quot;: &quot;Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-4\nPATHOLOGIC STAGINGt,u\nStage IA or IB\nStage lC\n(High-grade serous or\ngrade 2/3 endometrioid)\nStage II\nStage III\nStage IV\nIV platinum-based therapyn,v\n(see primary regimens for\nstage I disease [OV-C, 5 of 12])\nObserve\nor\nIntravenous (IV) platinum-based\ntherapyn,v (see primary regimens for\nstage I disease [OV-C, 5 of 12])\nMonitoring/\nFollow-up\n(OV-6)\nMaintenance\nTherapy (OV-5)\na CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due\nto anaphylaxis) and is preferred in select patients with renal dysfunction over CT.&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.642076849937439,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 14,
    &quot;text&quot;: &quot;Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-7\nDISEASE STATUSf,dd,ee\nPlatinum-resistant diseaseff:\nProgression on primary,\nmaintenance or recurrence therapy\nor\nStable or persistent disease\n(if not on maintenance therapy)\nor\nComplete remission and relapse &lt;6\nmo after completing chemotherapy\nPlatinum-sensitive diseaseff:\nComplete remission\nand relapse ≥6 mo\nafter completing prior\nchemotherapy\nf See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian,\nPancreatic, and Prostate and NCCN Guidelines for Genetic/Familial High-Risk Assessment:\nColorectal, Endometrial, and Gastric.\nn See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.640609860420227,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\n• Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n ◊If not previously used (category 1)\n ◊If disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6383495330810547,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 4,
    &quot;text&quot;: &quot;• Bevacizumab used as part of primary therapy\n\u0017BRCA1/2 wild-type or unknown, HR deficient, maintenance therapy regimen added: Olaparib (category 2B).\nLCOC-7\n• Recurrence therapy\n\u0017Specific regimens removed from this page; all listed in Systemic Therapy sections (OV-C 8 and OV-C 9).\nOV-C (8 of 12)\n• Useful in Certain Circumstances\n\u0017For low-grade serous carcinoma, regimen added: Avutometinib/defactinib (for KRAS-mutated tumors).\nOV-C (9 of 12)\n• Useful in Certain Circumstances\n\u0017For low-grade serous carcinoma, regimen added: Avutometinib/defactinib (for KRAS-mutated tumors).\nOV-C (11 of 12)\n• Reference added: Banerjee S, Nieuwenhuysen EV, Santin A, et al. Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A\nsubgroup analysis of ENGOTOV60/ GOG-3052/RAMP 201 Part A. Gyn Oncol 2024;190:S55-S56.\nUpdates in Version 1.2025 of the NCCN Guidelines for Ovarian Cancer from Version 3.2024 include:\nGlobal\n• References have been updated throughout the Guidelines.\n• Imaging footnote revised throughout OV and LCOC algorithms: CT is performed with oral and iodinated IV contrast (unless contraindicated due to&quot;
  }
]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- For first recurrence of epithelial ovarian cancer, platinum-based chemotherapy is preferred when appropriate; this recommendation is category 1 for platinum-sensitive relapse [4].  
- Secondary cytoreductive surgery should be considered at recurrence, with decision based on disease distribution, performance status, and likelihood of achieving complete resection [4].  
- If bevacizumab was used as part of primary therapy and the tumor is BRCA1/2 wild-type or unknown but homologous recombination–deficient (HRD), olaparib maintenance can be added; this is a category 2B recommendation [5].  
- NCCN systemic therapy options for recurrence are consolidated on the systemic therapy pages (OV-C 8 and OV-C 9), and should be used to select specific regimens based on platinum sensitivity and prior treatments [5].  
- For patients not suitable for further active oncologic treatment or declining therapy, best supportive care/palliative care should be integrated per NCCN Palliative Care guidelines [4].  
- The NCCN ovarian cancer recommendations cited are category 2A unless otherwise indicated, implying uniform consensus based on lower-level evidence; category 1 where specifically noted reflects high-level evidence with uniform consensus [1][2][3][5].</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Global Guideline RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-17T23:51:37.707289&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-07-25 15:38:50.183000&quot;,
      &quot;meta_info&quot;: &quot;422801196102010048&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:51:37.707717&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;925c44de16cb&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:51:37.966222&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 0,
      &quot;img_n&quot;: 0,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 0,
      &quot;cutoff_dt&quot;: &quot;2023-07-26 15:38:50&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:51:38.022000&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:52:35.965975&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;High‑grade serous ovarian carcinoma, platinum exposure limited (2 cycles); extensive peritoneal/omental/colon wall/diaphragmatic involvement; BRCA1/2 and HRD negative, PIK3CA positive, TP53 mutated; postoperative left ovarian vein thrombosis—guideline‑based systemic therapy and maintenance options?&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:52:35.965985&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:52:41.388442&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:54:10.800029&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 3018
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:54:10.800786&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:54:14.918538&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 1271
    }
  }
]</pre>
  </details>

</body>
</html>
